Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Treatment Solutions Network" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Treatment Solutions Network for you to read. Along with our medical data and news we also list Treatment Solutions Network Clinical Trials, which are updated daily. BioPortfolio also has a large database of Treatment Solutions Network Companies for you to search.
First Choice Healthcare Solutions Inc (OTCQB:FCHS) CEO Chris Romandetti tells Proactive Investors the health care delivery platform is receiving US$7.5mln from Steward Health Care System. Romandetti says the strategic opportunity between First Choice and Steward allows First Choice to deploy assets into Steward's network of 36 hospitals in the US.
"As Nevada's largest quality addiction treatment provider, we are dedicated to patient safety," said Regional Vice President of Nevadaand Solutions Recovery CEO David Marlon Read more...
Lawsuits have been filed against many pharmaceutical companies for the opioid crisis, but this doesn’t solve opioid addiction problems. As such, here the Investing News Network looks at six opioid use disorder treatment stocks. The post 6 Opioid Use Disorder Treatment Stocks appeared first on Investing News Network.
PETACH TIKVA, Israel, Sept. 5, 2018 /PRNewswire/ -- ECI, a global provider of ELASTIC Network® solutions for service providers, critical infrastructures and data center operators, Read more...
TriNetX, the global health research network, today announced the availability of TriNetX Research, a suite of analytics solutions to leverage real-world data when conducting observational and outcomes research. TriNetX Research combines longitudinal clinical and genomic data from its global network with powerful, state-of-the-art analytics on a single self-service platform. Researchers will now ha...
SOURCE: Aflac DESCRIPTION:As a national ambassador for Children’s Miracle Network Hospitals, Chloe, age 11, is just one of 10 million children treated each year at Children’s Miracle Network Hospitals. This past week, Chloe took to the sky to fly to Columbus, GA, home of Aflac, a Children’s Miracle Network Hospitals partner to participate in a video shoot to create her story on surviving c...
Arbutus Biopharma (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company’s lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals, (Nasdaq:ALNY), announced that their new drug application (NDA) for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of heredit...
In the rush to install EMRs tech folks often forget that you need to make sure that your network can handle the (usually significant) load that medical records automation will add to your network infrastructure. I invited Jon Mills of of Plixer International, Inc., a Maine-based software development company that specializes in network traffic analysis using NetFlow and other flow-based monitoring ...
The NSA’s unclassified 60 Minute Network Security Guide is a great way to check that your network security is up to par with the nation’s pre-eminent spy agency’s guidelines. Check it out and see if your network measures up — leave some comments here to tell us what you think about the guidance provided.
AZEDRA treats patients 12 and older with two different types of rare tumors–pheochromocytoma or pragaglioma–and is the first FDA approved treatment for this type of treatment. The post Progenics Receives FDA Approval for Rare Tumor Treatment appeared first on Investing News Network.
Reimbursify, a healthcare-focused technology company providing app-centric solutions for consumers, healthcare providers & businesses has launched a new app that gives patients a quick and easy way to file out-of-network reimbursement claims with their insurance company in less than 60 seconds. Users can also monitor their current, pending, and past claims from the app. Reimbursify is curre...
Inspire Medical (NYSE:INSP) a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that Aetna Inc., one of the leading health plans in the United States, will provide coverage for the Company’s Inspire therapy, effective immediately. Aetna’s plan provides cov...
University of Virginia Health System is partnering with more than 20 other health systems in the AVIA network's Medicaid Transformation Project to develop financially sustainable solutions to improving the health of the nearly 75 million Americans who receive Medicaid.
In a wide-ranging scheme, AbbVie used a combination of old-fashioned kickbacks to doctors and a stealthy network of nurses to illegally boost prescriptions of its best-selling Humira treatment.
When patients go to an in-network facility, they can still be treated by an out-of-network medical professional--anesthesia or pathology claims being among the most common.
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug develo...
Quantzig, a global analytics solutions provider, has announced the completion of their latest transport network optimization study on the dental implants industry. The client, a leading dental implants manufacturer, wanted to reduce the distribution costs and meet the needs of the end-user segments in the medical implants space. This press release fe...
BRENTWOOD, Tenn. (PRWEB) August 01, 2018 Matt Feehery has been named Chief Executive Officer at Foundations Recovery Network (FRN) and Vice President, Addiction Treatment Services, Behavioral Health Division of Universal Health Services (UHS) , effective July 30, 2018. He will lead the Add...
The company said that the drug has a projected availability date of August 2018 in US retail pharmacies. It is the first FDA-approved oral treatment for alleviating pain associated with endometriosis. The post AbbVie Notches FDA Approval for Endometriosis Pain Treatment appeared first on Investing News Network.
The GuardianIVF services slashed in England as NHS bosses cut costsThe GuardianA growing number of areas in England have axed IVF treatment on the NHS and the proportion offering the recommended three cycles of treatment has fallen to just over one in 10, the Guardian can reveal. The data, gathered by the Fertility Network UK ...Health warning on NHS treatment banThe Timesall 5 news articles
TriNetX, the global health research network, will announce the latest addition to its research network: Carilion Clinic, a not-for-profit healthcare organization based in Roanoke, Virginia. By joining the network, Carilion will enhance its researchers’ ability to quickly execute clinical trials and collaborate with other industry TriNetX network members. Carilion, serves nearly one million res...
Announces $93 million investment round to accelerate expansion of information-sharing network platform across life sciences
Here at the Investing News Network our mission is twofold; to provide the latest news and quality education by helping you identify investment opportunities in niche markets, and helping leading companies communicate their value to investors. The post New to the Investing News Network appeared first on Investing News Network.
5G-evolution core network modernization will deliver increased reliability, thanks to cloud architecture, greater flexibility and services customization, thanks to network slicing Solution improves speed, efficiency Read more...
(PLOS) Current recommended dosing regimens for the most widely used treatment for uncomplicated Plasmodium falciparum malaria may be sub-optimal for the most vulnerable populations of patients, according to a study published this week in PLOS Medicine, led by Professor Joel Tarning of the WorldWide Antimalarial Resistance Network and the Mahidol Oxford Tropical Medicine Research Network.